Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
1998-02-27
2001-07-03
Myers, Carla J. (Department: 1655)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S091200, C435S091500, C435S091510, C536S023500, C536S024310, C536S024330
Reexamination Certificate
active
06255049
ABSTRACT:
Throughout this application, various references are referred to within parentheses. Disclosures of these publications in their entireties are hereby incorporated by reference into this application to more fully describe the state of the art to which this invention pertains.
BACKGROUND OF THE INVENTION
Adenocarcinoma of the prostate is the most common internal cancer of men in the United States and the second most frequent cause of cancer death (1). Identification of immunological and genetic reagents displaying specificity for prostate carcinoma versus normal prostate and BPH will be of immense value for the accurate diagnosis and possibly for the therapy of prostate cancer (2-6). Additionally, immunological reagents that can detect and bind to TAAs on the surface of prostate carcinoma cells, and that display limited expression on normal prostate and BPH tissue, may also prove of particular benefit for the detection and ultimately, therapy of prostate cancer (4,7,8).
Two novel approaches have been developed for defining the molecular and immunological basis of human cancer. One approach, the REXCS (2,3), permits the identification of putative oncogenic elements in human cancer DNAs. RExCS involves cotransfection of high molecular weight human tumor DNA in combination with a selectable antibiotic resistance gene into a new DNA acceptor cell line, CREF-Trans 6, selecting antibiotic resistant cells, injecting these cells into nude mice, and establishing cell cultures from tumors developing in athymic nude mice (2,3). Tumor-derived cell lines are then used to identify the putative human oncogenes, using approaches such as differential RNA display, that have been transferred from the human cancer cells into CREF-Trans 6 (3). Another methodology, SEM (7,8), results in the efficient and selective production of monoclonal antibodies reacting with tumor associated antigens present on the surface of human cancer cells (4,7,8). This procedure involves immunological subtraction based on the selective blocking of surface antigens on genetically altered cells (referred to as a “tester”) with high titer polyclonal antibodies produced against untransfected parental cells (referred to as a “driver”) This is followed by the production of hybridomas secreting MAbs that react with defined as well as uncharacterized cell surface expressed molecules (7,8).
Using SEM in combination with RExCS, prostate carcinoma (Pro 1.5) MAbs have been developed that react with TAAs expressed on human prostate cancer cell lines and patient-derived carcinomas (4,7,8). Addition of the Pro 1.5 MAb to nude mice containing human prostate cancer xenografts suppressed tumor growth and cancer progression. Screening a human LNCaP prostate cancer cDNA expression library with the Pro 1.5 MAb identified PCTA-1, a gene that encodes a novel galactose binding lectin, designated galectin-8HT (7). PCTA-1 was previously described in International Application No. PCT/US96/00307, filed Jan. 11, 1996, and published on Jul. 18, 1996 under International Publication No. WO 96/21671, which is herein incorporated by reference.
Using primer pairs corresponding to the 3′ untranslated (UTR) region, RT-PCR detected PCTA-1 expression in prostatic carcinomas and PIN, but not in histologically confirmed normal prostate or BPH (7). Although further studies are necessary using a larger number of patient samples, these provocative results suggest that the Pro series of murine MAbs and the PCTA-1 gene should have direct diagnostic applications for human prostate cancer. Moreover, if the Pro MAbs show specificity toward prostate cancer, appropriately modified Pro MAbs, including chimerized and humanized versions of this MAb, may have therapeutic potential in patients with primary and metastatic prostate cancer.
PCTA-1 encodes a predicted protein structurally related to the S-type lectins (galectin) gene family (7). The galectins display wide tissue distribution, developmental regulation and differential expression levels in specific tissues, supporting the hypothesis that they contribute to many physiologically important processes in mammalian cells (9,10). Of direct relevance to cancer is the finding that the galectins, as well as the selectin subgroup of C-type lectins, mediate both cell-cell and cell-matrix interactions (10,11). These associations are critical elements in mediating the metastatic spread of tumor cells (12,13).
SUMMARY OF THE INVENTION
This invention provides a method of detecting cancer metastatic cells in a subject, comprising: a) obtaining a nucleic acid sample from the subject's blood; b) amplifying nucleic acid encoding the product of prostate carcinoma tumor antigen gene-1; and c) detecting the presence of nucleic acid encoding the product of the prostate carcinoma tumor antigen gene-1, thereby detecting cancer metastatic cells in a subject.
This invention also provides a method of determining the stage of cancer in a subject, comprising: a) obtaining a nucleic acid sample from the subject's blood; b) amplifying the nucleic acid encoding the product of prostate carcinoma tumor antigen gene-1; and c) quantifying the levels of RNA encoding the product of prostate carcinoma tumor antigen gene-1, thereby determining the stage of cancer in a subject.
This invention also provides the above-described methods, wherein the method of amplification is PCR.
Further, this invention provides the above-described methods, wherein the one of the primers is 5′-AAGCTGACGCCTCATTTGCA-3′ SEQ ID NO:1.
This invention also provides the above-described methods, wherein the one of the primers is 5′-AACCACCAATGGAACTGGGT-3′ SEQ ID NO:2.
This invention further provides the above-described methods, wherein the primers are 5′-AAGCTGACGCCTCATTTGCA-3′ SEQ ID NO:1 and 5′-AACCACCAATGGAACTGGGT-3′ SEQ ID NO:2.
In addition, this invention provides the above-described methods, wherein the one of the primers is 5′-AATGGCTTCTGTGATACT-3′ SEQ ID NO:3.
Further, this invention provides the above-described methods, wherein the one of the primers is 5′-GGCTATAAGTGTTGCTGC-3′ SEQ ID NO:4.
This invention also provides the above-described methods, wherein the primers are 5′-AATGGCTTCTGTGATACT-3′ SEQ ID NO:3 and 5′-GGCTATAAGTGTTGCTGC-3′ SEQ ID NO:4.
This invention also provides a method of detecting prostate cancer metastasis in a subject, comprising: a) obtaining a nucleic acid sample from the subject's blood; and b) applying a labeled probe that specifically hybridizes to the nucleic acid encoding the product of the prostate carcinoma tumor antigen gene-1, wherein the labeled probe produces a signal for detection and said signal amplifies detection of the probe.
This invention further provides the above-described methods, wherein the labeled probe comprises an enzyme that produces a detectable product, thereby amplifying detection of the probe.
REFERENCES:
patent: 96 21671 (1996-07-01), None
Fisher, P., B., (1995) “A new technology for preparig monoclonal antibodies to molecules expressed on the cell surface”,Pharmaceutical Tech. 19(9):42-48, (Exhibit 2).
Gronberg, H., et al., (1997) “Early age at diagnosis in families provided evidence of linkage to the hereditary prostate cancer locus (HPCI) on chromosome 1”,Cancer Res. 57:4707-4709, (Exhibit 3).
Raz, A. and Lotan, R., (1987) “Endogenous galactoside-binding lectins: a new class of functional tumor or cell surface molecules related to metastasis”,Cancer Metastasis Rev, 6:433-452, (Exhibit 4)
Shen, R., et al., (1994) “Surface epitope masking: a strategy for the development of monoclonal antibodies specific for molecules expressed on the cell surface”,J. Natl. Cancer Inst. 86:91-98, (Exhibit 5).
Smith, J.R., et al., (1996) “Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search”,Science274:1371-1375, (Exhibit 6).
Su, Z-Z, et al., (1996) “Surface-epitope masking and expression cloning identifies the human prostate carcinoma tumor antigen gene PCTA-1 a member of the galec
Cooper & Dunham LLP
Johanssen Diana
Myers Carla J.
The Trustees of Columbia University in the City of New York
White John P.
LandOfFree
Detection of metastatic cancer cells using PCTA-1 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Detection of metastatic cancer cells using PCTA-1, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Detection of metastatic cancer cells using PCTA-1 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2447915